Introduction
============

According to the 2007 Report of the International Dry Eye Workshop,[@b1-opth-10-331] dry eye is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort,[@b2-opth-10-331]--[@b4-opth-10-331] visual disturbance,[@b5-opth-10-331]--[@b7-opth-10-331] and tear film instability[@b8-opth-10-331]--[@b10-opth-10-331] with potential damage to the ocular surface.[@b11-opth-10-331] It has been estimated that approximately 5 million Americans 50 years and older have moderate-to-severe forms of dry eye, with millions more affected by less severe forms of the disease.[@b12-opth-10-331],[@b13-opth-10-331] While dry eye has traditionally affected older patients, the population of dry eye sufferers has been trending toward a younger age group in recent years. This is likely due to factors such as increases in laser vision correction procedures, chronic ocular allergies, and the growing numbers of persons who perform visual tasks over long period of time.[@b14-opth-10-331]

The varying severity and complexity of dry eye make it a challenging disease to treat. Without proper treatment, dry eye disease can adversely affect the quality of life,[@b15-opth-10-331] visual function,[@b16-opth-10-331] contact lens tolerance,[@b17-opth-10-331] and refractive surgery outcomes.[@b18-opth-10-331] Lubricant eye drop (also known as artificial tear) remain as the first line of treatment for dry eye and are commonly used to supplement for deficient natural tears.[@b19-opth-10-331] Like most multidose topical formulations for ocular use, these tear substitutes contain preservatives to inhibit microbial contamination. While preservatives are not required in unit dose vials, these nonpreserved preparations are more costly for the patients to purchase and less convenient to use than ocular lubricants in multidose packaging. Among common ophthalmic preservatives, benzalkonium chloride (BAK, BZK, or BAC) was the first ophthalmic preservative and has been in use for over 60 years.[@b20-opth-10-331] BAK is a quaternary ammonium surfactant preservative and is currently used in over 70% of ophthalmic products on the market.[@b21-opth-10-331] While the preservative efficacy (PE) of BAK is well established, it has also come under scrutiny over the years for its potential to disrupt the precorneal tear film and damage the epithelial surface of the cornea, especially for dry eye patients who use the product frequently.[@b22-opth-10-331]--[@b27-opth-10-331] To avoid the potential risks associated with BAK use in dry eye patients, many commercially available tear substitute products now offer preservative-free or BAK-free solutions.

A systematic development program was initiated to identify, characterize, and validate a novel, safe, effective, and gentle preservative as an alternative to BAK. The preservative was required to meet three fundamental criteria: 1) potency of PE; 2) potential lack of ophthalmic or systemic toxicity based on available literature data; 3) potential lack of reactivity to other commonly used ophthalmic ingredients.

After a thorough literature search, a list of preservatives that may have potential for ophthalmic use was generated. A preservative effectiveness test on all preservatives using a lubricant eye drop formula without BAK was carried out, and the products with adequate PE were selected. Subsequently, a series of in vitro studies including transepithelial permeability, fluorescein leakage, and the neutral red uptake cytotoxicity procedure were conducted using BAK as the negative control. Results from the neutral red uptake procedure were most discerning regarding the cytotoxicity of the preservatives. On the basis of all the in vitro test results, polyquaterium-42 (GentlePur™) demonstrated superior preservative effectiveness and much less irritability than BAK.

GentlePur™ is a quaternary ammonium cationic surfactant polymer that contains straight polyethylene chain segments. In comparison, BAK is a quaternary ammonium cationic surfactant monomer that contains benzyl rings segments. Although both are highly effective antimicrobial agents. GentlePur™ has extremely low ocular irritancy and has been used as a preservative in contact lens solutions and lubricant eye drops.[@b28-opth-10-331],[@b29-opth-10-331]

The purpose of this study was to evaluate the comfort and safety of a new formulation of Visine^®^ (Johnson & Johnson, New Brunswick, NJ, USA) lubricant eye drops containing GentlePur™ and 0.2% glycerin, 0.36% hypromellose, and 1% polyethylene glycol 400 "Hydroblend™" in healthy and dry eye subjects.

Methods
=======

Study population
----------------

This study was conducted in compliance with the ethical principles of Good Clinical Practices, the Declaration of Helsinki, the International Conference on Harmonization guidelines, and all applicable local and federal requirements relevant to the use of investigational drugs. The study employed a single-site, open label, investigator-masked protocol. The two study groups enrolled 22 subjects each; one group of subjects was a healthy control group, the other group of subjects had a confirmed diagnosis of dry eye. Inclusion criteria for both groups were as follows: subjects needed to be at least 18 years old, follow all study directions, and attend all required visits, and provide written informed consent for study participation. All subjects had corrected visual acuity of logMar +0.5 (ETDRS, Early Treatment Diabetic Retinopathy Study) or better in each eye and good overall ocular health (with the exception of the dry diagnosis). Subjects were excluded if they had used contact lenses within 1 week of the study or were planning to wear contacts within the anticipated study timeframe; had any active ocular inflammation or allergy; had used any topical ophthalmic agents within 7 days of the study; had ever undergone laser-assisted in situ keratomileusis, surgery for neurotrophic keratitis or corneal transplant; had any ocular surgery within 6 months; or were currently using any systemic medication known to cause ocular dryness. Subjects with known sensitivities to any study components or those with any medical condition that could affect study parameters were also excluded, as were women of childbearing age who were pregnant or unwilling to use approved birth control for the duration of the study. Subjects who had participated in any other clinical trial in the previous 30 days were also ineligible. To qualify for the dry eye group, subjects were required to have a history of lubricant eye drop use in the previous 12 months, and fluorescein corneal staining score ≥1 (National Eye Institute \[NEI\] scale) in any of the five regions and a total score \<7 in one eye; subjects who did not meet both of these criteria, or subjects with a history of lubricant eye drop use ≥6 times per day, were excluded from both control and dry eye groups.

Test product
------------

The test product is a prototype lubricant eye drop formulation. It combines Hydroblend™ (0.2% glycerin, 0.36% hypromellose, and 1% polyethylene glycol 400) and the preservative GentlePur™ (polyquaternium-42).

Study protocol
--------------

The study duration was 2 weeks. Each subject attended three study visits: visit 1 (day 0, baseline), visit 2 (day 7±1), and visit 3 (day 14±1). Following baseline assessment on day 0, all subjects were provided with test lubricant eye drop and instructed to instill the drops into each eye (1--2 drops) four times a day for 14 days. Assessments conducted at each visit included visual acuity, ocular structure change using slit-lamp biomicroscopy, and fluorescein corneal staining (inferior, superior, central, temporal, nasal) based on the NEI scale of 0--3[@b30-opth-10-331],[@b31-opth-10-331] (0= normal and 3= severe). Product usage comfort assessments were conducted at visits 1 and 3 for each eye immediately and at 1, 2, and 3 minutes postdosing using a scale ranging from 0 to 10, with 0 being very uncomfortable and 10 being very comfortable. The assessment schedule is summarized in [Table 1](#t1-opth-10-331){ref-type="table"}. Additionally, adverse events were monitored and recorded throughout the entire course of the study.

Statistical analysis
--------------------

Forty-four subjects, 22 healthy and 22 with dry eye, were enrolled in the study. One dry eye subject was discontinued after visit 1 due to noncompliance (unable to attend visit 2). Sex was summarized by numbers and percentages, and age was summarized by means and standard deviations. Scores for each eye were obtained for visual acuity, product usage comfort, and corneal staining (inferior, superior, central, temporal, nasal, and average over the five regions). These were averaged over the two eyes to give corresponding subject-level scores, and the subject-level scores were averaged over all subjects to give mean group scores.

Results
=======

Study population
----------------

A total of 56 subjects were screened to identify 22 subjects for each study group. After the study began, one subject from the dry eye group was discontinued due to noncompliance. A summary of demographics is presented in [Table 2](#t2-opth-10-331){ref-type="table"}. Overall, the dry eye group was somewhat older and had a larger number of women, as expected from the prevalence of the disease in the general population.

Product usage eye comfort score
-------------------------------

At the first (visit 1) and last (visit 3) study visits, subjects were asked to provide assessments of drop comfort for each eye immediately after instillation and at 1, 2, and 3 minutes following instillation. The assessments used a 0--10 point scale, where 0 is very uncomfortable and 10 is very comfortable. Mean values of four time points at each visit, shown in [Table 3](#t3-opth-10-331){ref-type="table"} and [Figure 1A and B](#f1-opth-10-331){ref-type="fig"}, are all 8.50 or higher for all time points, visits, and subject groups.

Corneal staining score
----------------------

Fluorescein staining of the corneal surface from inferior, superior, central, temporal, nasal region, and an average over the five regions based on the NEI scale of 0--3 (0= normal and 3= severe) was assessed and the results are included in [Table 4](#t4-opth-10-331){ref-type="table"}.

For the dry eye group, the five-region corneal staining scores improved from visits 1 to 3. The average staining scores over the five regions of the cornea were 0.65 at visit 1, 0.75 at visit 2, and 0.39 at visit 3. A decrease in corneal fluorescein staining from baseline (visit 1) to visit 3 for dry eye group is presented in [Figure 2](#f2-opth-10-331){ref-type="fig"}.

For the healthy group, the corneal staining scores at baseline were very low (0.15) and they showed very little changes from baseline at visits 2 and 3.

Visual acuity
-------------

Averaging over both eyes, pretreatment (baseline) visual acuity means on the logMAR scale were 0 and -0.02 for the dry eye subjects and healthy subjects, respectively. For both groups, visual acuity means were maintained at visit 2 and improved by 0.03 at visit 3.

Ocular structure using slit-lamp biomicroscopy
----------------------------------------------

Slit-lamp biomicroscopy was conducted on four ocular structures (lid, lens, conjunctiva, and cornea) predose and postdose at all three visits for a total of six time points. For all structures, the five posttreatment findings showed no change from visit 1 pretreatment findings.

Adverse events
--------------

In addition to the acuity and slit-lamp examinations, a tabulation of all reported adverse events was used in the overall safety assessment. Reported adverse events were mild and did not require action to mitigate the effects observed. Two dry eye subjects had a total of four adverse events from the entire study population. Two adverse events (filmy vision upon instillation and blurred vision after instillation) were related to the study medication. The other two adverse events (ocular redness and increased tears) were possibly related to the study medication. All adverse events were assessed as mild and nonserious. There were no discontinuations due to the study medication.

Discussion
==========

In order to determine the potential for ocular irritation by GentlePur™ and provide data to support its use in humans, a rabbit study was conducted. In this study, ten rabbits were dosed with lubricant eye drops preserved with GentlePur™ six times daily for 30 consecutive days. This study established that topical administration of the preservative was nontoxic and nonirritating in the rabbit eye test system.

In the current study, GentlePur™ preserved lubricant eye drops were tested for eye comfort and safety in both a healthy control group and in subjects with mild dry eye disease. At the beginning and the end of 2 weeks of treatment, all subjects found the product to be comfortable to use, with product usage eye comfort means of 8.5 or higher on a scale of 0--10, where 0 is very uncomfortable and 10 is very comfortable, indicating a high tolerance of the test product for both dry eye and healthy eye subjects. From visits 1 to 3, the eye comfort score at each time point (immediately, 1, 2, and 3 minutes after dosing) and mean eye comfort score over four time points increased numerically for dry eye subjects and maintained nearly no change for healthy eye subjects ([Table 3](#t3-opth-10-331){ref-type="table"} and [Figure 1A and B](#f1-opth-10-331){ref-type="fig"}).

Corneal fluorescein staining has been recognized as a reliable clinical measurement for ocular surface condition and is correlated with the severity of dry eye. Per study protocol inclusion criteria, dry eye subjects were selected with corneal staining score of ≥1 in any of the five regions on the NEI scale in at least one eye. Therefore, it is expected that dry eye group had higher baseline corneal fluorescein staining score than that of healthy subjects in all five corneal regions. Although the corneal staining score increased from visits 1 to 2, it decreased from visits 1 to 3 for all five regions in dry eye group, indicating an overall improvement from the new lubricant eye drop treatment for dry eye patients. For the healthy eye group, the mean baseline corneal staining score was very low (0.15) and remained very low (0.10) at the end of the 2-week treatment, indicating no increase of eye dryness for healthy eye subjects ([Table 4](#t4-opth-10-331){ref-type="table"} and [Figure 2](#f2-opth-10-331){ref-type="fig"}).

Over the trial period there was also no evidence of deteriorating outcomes in visual acuity following treatment. In fact, similar to corneal staining, there was a tendency for slight improvement from visits 1 to 3. Product usage comfort increased slightly with use for dry eye subjects and was fairly consistent for healthy subjects.

Slit-lamp biomicroscopic examination on four ocular regions did not find any structural change after 2 weeks of treatment from the baseline. While there were four adverse events reported in this study, all were considered to be mild and nonserious, as there were no discontinuations due to the study medication, and all four events resolved by the end of the study date or shortly thereafter.

Conclusion
==========

The prototype lubricant eye drop formulation from the makers of Visine^®^ combines a gentle and effective preservative GentlePur™ with unique Hydroblend™ technology to provide a new lubricant eye drop option for dry eye sufferers and can be used as often as needed as directed by label instructions.
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###### 

Safety assessment schedule

                     Product usage eye comfort score             Fluorescein corneal staining score   Visual acuity   Ocular structure/slit-lamp biomicroscope
  ------------------ ------------------------------------------- ------------------------------------ --------------- ------------------------------------------
  Visit 1 (day 0)    Immediate, 1, 2, and 3 minutes postdosing   Predosing                            Predosing       Predosing and 15 minutes postdosing
  Visit 2 (day 7)    Not measured                                Predosing                            Predosing       Predosing and 15 minutes postdosing
  Visit 3 (day 14)   Immediate, 1, 2, and 3 minutes postdosing   Predosing                            Predosing       Predosing and 15 minutes postdosing

###### 

Subject demographics

            Dry eye (N=22)                        Healthy (N=22)
  --------- ------------------------------------- -------------------------------------
  **Sex**   **N (%)**                             **N (%)**
  Female    18 (82%)                              13 (59%)
  Male      4 (18%)                               9 (41%)
  **Age**   **Mean (**± **standard deviation)**   **Mean (**± **standard deviation)**
  Female    54 (±12)                              38 (±11)
  Male      45 (±16)                              44 (±14)

###### 

Subject reported product usage comfort scores after product usage

                              Dry eye group   Healthy eye group               
  --------------------------- --------------- ------------------- ----------- -----------
  Immediate                   8.55±1.22       9.24±1.34           9.82±0.39   9.36±1.18
  1 minute                    8.68±1.09       9.62±0.80           9.77±0.53   9.64±0.79
  2 minutes                   8.50±1.26       9.57±0.87           9.73±0.63   9.86±0.35
  3 minutes                   8.82±1.00       9.52±0.92           9.64±0.95   9.90±0.29
  Mean ± standard deviation   8.64±0.90       9.49±0.80           9.74±0.59   9.69±0.54

**Note:** The values are given as mean ± standard deviation.

###### 

Mean corneal staining for dry eye and healthy eye groups from each region and average across five regions

                                Dry eye group   Healthy eye group                                       
  ----------------------------- --------------- ------------------- ----------- ----------- ----------- -----------
  Inferior                      1.02±0.11       1.35±0.1            0.83±0.11   0.27±0.11   0.34±0.11   0.39±0.10
  Central                       0.20±0.07       0.10±0.07           0.17±0.07   0.07±0.03   0.05±0.05   0.05±0.05
  Superior                      0.55±0.11       0.81±0.07           0.05±0.05   0.14±0.05   0.23±0.08   0.02±0.02
  Temporal                      0.48±0.10       0.62±0.09           0.29±0.09   0.07±0.04   0.07±0.03   0.05±0.03
  Nasal                         1.00±0.13       0.88±0.06           0.62±0.10   0.18±0.07   0.11±0.05   0.02±0.02
  Average across five regions   0.65±0.07       0.75±0.04           0.39±0.06   0.15±0.04   0.16±0.04   0.10±0.03

**Note:** The values are given as mean ± standard error.
